By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Epigenomics has raised approximately €33.1 million ($44.2 million) through a combined private and public share offering, which it will use for a variety of corporate purposes centered on expanding the market for its diagnostic tests and further developing tests in its product pipeline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.